Virapinib

Virapinib (0.78-25 μM; 6 h pre-incubation; 72 h total incubation post-virus addition) inhibits SARS-CoV-2 S pseudotyped lentivirus infection in HEK293T^ACE2 cells in a dose-dependent manner, but has no effect on VSVg pseudotyped lentivirus infection^[1].
Virapinib (0.5-10 μM; 6 h pre-incubation; 24 h total incubation post-virus wash-off) dose-dependently inhibits infection by the original SARS-CoV-2 in Vero E6 cells, with no cytotoxicity detected^[1].
Virapinib (1-20 μM; 6 h pre-incubation; 24 h total incubation post-virus wash-off) dose-dependently inhibits infection by the original SARS-CoV-2, reduces syncytium formation in A549^ACE2 cells, and shows no detectable cytotoxicity^[1].
Virapinib (0.5-10 μM; overnight pre-incubation; 24 h total incubation post-virus infection) effectively reduces the infectivity of SARS-CoV-2 in 3D primary human hepatospheres^[1].
Virapinib (5-25 μM; 16 h pre-incubation; 2 h dextran incubation) dose-dependently inhibits macropinocytosis in A549 cells and selectively blocks SARS-CoV-2 entry into A549^ACE2 cells via the macropinocytosis pathway^[1].
Virapinib (5-40 μM for tick-borne encephalitis virus and monkeypox virus; 10-25 μM for Ebola-pseudotyped vesicular stomatitis virus; 6 h pre-incubation) dose-dependently inhibits infections by tick-borne encephalitis virus, monkeypox virus, and Ebola-pseudotyped vesicular stomatitis virus in A549 cells. It shows no activity against Andes virus, only weak activity against adenovirus, and enhances dengue virus infection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.